GE Healthcare Submits the Final Module of Its Premarket Approval Application (PMA) for GE Breast Tomosynthesis Option
7/30/2013 9:43:34 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
WAUKESHA, Wis.--(BUSINESS WIRE)--GE Healthcare, a unit of General Electric Company (NYSE:GE), announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval application (PMA1) for GE Breast Tomosynthesis, an option of the Senographe* Essential system.
Help employers find you! Check out all the jobs and post your resume.
comments powered by